The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Count Me In, a non-profit research initiative that conducts patient-partnered studies of cancer, were awarded a $16 million grant from NCI to accelerate research in two rare forms of cancer.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
